De-cancer / curatio /-orci iudiciis / morbo / melanoma, intraocular / curatio
Carcinoma in Tono curatio Fusce Tribulationes
Research studiis, quae sunt orci iudiciis involvere populo. De hac list orci iudiciis intraocular sunt melanoma, quia curatio. Iudiciis omnibus in album NCI fulciuntur.
NCI est scriptor basic notitia super orci iudiciis et genera et tempora et quomodo tribulationes sunt ferri ex. At orci iudiciis ne novus via, deprehendere, non facies morbo. Vos may volo ut cogitare de participantes Conventum per iudicium orci. Disputatio ad tuum auxilium medicus et in statuendi ius, si est tibi.
XXV De iudiciis 1-25
Incolumitatem et Efficacia IMCgp100 Investigator versus est in arbitrio Advanced uveal melanoma
* A-HLA erectum est aestimare et altiore salvos CCI positivum adulta prius increatos aegris cum provectus UM electio accepto IMCgp100 comparari Investigator dacarbazine, ipilimumab aut pembrolizumab.
Location: XIX locus
DE PATRIS XmAb®22841 MONOTHERAPY deducto & w / Pembrolizumab in subiecto w / Advanced solidum Lego Usu
Hoc Phase I: plures qui iamiam terminantur, consectetuer sit offerre et holocausta, et propagationis eorum studium studium expansion disposito maximum definias, ut tolerari pondere et / vel commendatur, et iunctum cum pondere XmAb22841 MONOTHERAPY pembrolizumab; perpendere salute tolerability, Farmacocinética, Vertebrata et anti-tumore actio XmAb22841 MONOTHERAPY selectis et cum respectu subiectorum pembrolizumab solida processit tumores.
Location: X locus
Studio et RP1 MONOTHERAPY RP1 deducto In Nivolumab
001-16, RPL est phase istud I / II, aperta pittacium, and expansion PROLATIO consectetuer orci studiis RP1 solus et cumulative cum adulta nivolumab in rebus versatur provectus et / vel solidum secretiori parte natium refractarium, tolerabat maxime determinare dose (BERC) Phase II pondere atque commendatae (RP2D), tum parata est aestimare an et efficacia mirabilia.
Location: VI locus
Parvus et in studiis Series Prima choroideae Carcinoma
In prima est objective assident salutem, simulque efficacitate adiumentum Vertebrata unius tribus ex consectetuer consectetuer repeat gradus et catholicorum, diaetam ipsis autem lux-XI-activated AU unum vel duos applications pro laser capillus treatment in prima rerum choroideae melanoma.
Location: IV locus
In Solidum aegroti sunt in studiis IDE196 Usu hospitio GNAQ / XI, vel mutationibus PRKC Fusiones
Hic est Status I / II, multi-centrum, aperto-titulus canistro studio disposito ad aestimandas salute et anti-tumore actio et IDE196 in aegris cum solidum secretiori parte natium hospitio GNAQ aut GNA11 (GNAQ / XI) mutationes et PRKC fusions, inter metastatic uveal melanoma (ST) transpiratio melanoma, colorectal cancer et aliis solidum similitudines anorum. Tempus I (PROLATIO consectetuer) erit assident salutem, per vexillum IDE196 tolerability et Farmacocinética in pondere et in propagationis ordinem ad determinare dose II suadetur tempus. Anti-tumore actio et salutem, et in ea quoque pars II (dose expansion) partem studio.
Location: IV locus
Selumetinib Sulfate in his quae sunt aegroti, vel uvea Carcinoma GNAQ / GNA11 Mutated Carcinoma Metastasico uidetur quod non, vel non exemptile Surgery
Hoc tempus iudicii lb studiis latus effectus et maxime cum de aegris cum uvea et rubore laudabunt selumetinib sulfate melanoma vel GNAQ / mutatur GNA11 melanoma quae primaria propagationem ex aliis locis situm in corpore vel non amoveatur ab surgery. Selumetinib sulfate, ut tumore cellulis luxuries vetuit nasci quidam enzymes opus ad cellulam incrementum impediret.
Location: III locis
De Viris Illustribus Magis Aquilo quam mutatio, cum aegroti IFNbetaTYRP1 ubi spectacula theatrica II, III Carcinoma
Tempus et iudicium haec studia optima et rubore laudabunt latus effectus et vocavit virum Magis Aquilo quam mutatio de III-IV-scaena IFNbetaTYRP1 dum de aegris cum melanoma. De vesicular stomatitis virus (Magis) has litteras destinavimus, ut includit duo extra genes: humano interferon beta (hIFNbeta), cuius praesidio normalis sanus cellulis a contagiosissimo virum et TYRP1 consistit, quae maxime in melanocytes (specialized cutis cell est cutis-obtenebratio dat tutela melanin-pigmento) et melanoma tumore cellulis et potest trigger fortis immune responsio ad melanoma, ut tumore cellulis occidere.
Location: II locus
DE PATRIS in PLX2853 Advanced Malignancies.
Et ad hanc investigationis studium est ad aestimandas salute, Farmacocinética, et propedeutica Pharmacodynamics efficaciam medicamento investigational PLX2853 provectus malignancies in rebus versatur.
Location: II locus
Yttrium90, Ipilimumab, & Nivolumab iecoris metastases Cum enim uveal melanoma
Renuntiationes limitata ad diem ostendit efficaciam immunotherapy uvee est melanoma. Recent insinuat quod synergy inter experimentum et orci Lorem et immunotherapy radialem. Inquisitores et synergy quod explorandum est a FACULTAS studio XXVI aegris cum uvea melanoma et hepaticum metastases qui SirSpheres accipere XC-electionem selectivam Yttrium hepaticum internum sequitur immunotherapy cum radii compositum ipilimumab et nivolumab.
Location: II locus
Pegargiminase, Nivolumab Ipilimumab et in his quae sunt aegroti Advanced uveal melanoma vel Unresectable
Haec studia tempus iudicii non ex ea parte effectus pegargiminase, et nivolumab ipilimumab in his aegris per propagationem uveal melanoma quae aliis locis in corpore (provectus), vel potest non remota a surgery (unresectable). Ut tumore cellulis Pegargiminase luxuries vetuit nasci tutabantur quidam enzymes opus ad cellulam incrementum. Virus immunotherapy elementorum et qualis nivolumab ipilimumab ac, feugiat oppugnare auxilium corporis cancer cellulis tumor incrementum fortasse facultate et multiplicabatur. Pegargiminase dare, et nivolumab ipilimumab potest melius comparari immunotherapy solus.
Location: Memorial Center Cancri Keteryng asperatus, New York, New York
Corpus Stereotactic Radiation Therapy cum aegroti uveam et tractant Carcinoma in Aflibercept
Hoc Phase II iudicium studiis Stereotactic tam corporis quam in his aegris per radialis justo et aflibercept opus uveal melanoma. Radiatio corporis Stereotactic Lorem apparatu utitur specialis situm in secretiori parte natium patientes estote ad emissionem radiationemque, et libera cum summus praecisione. Supra modum hic possunt occidere tumore cellulis paulatim in paucioribus et minus potest facere minus damnum ad normalis TEXTUS. Ut tumore cellulis Aflibercept luxuries vetuit nasci tutabantur quidam enzymes opus ad cellulam incrementum. Radiatio corporis Stereotactic dare Lorem sequitur aflibercept potest melius operari in his aegris cum uvea melanoma.
Location: Thomas Universitatis hospitalis, Philadelphia, Pennsylvania
Safety et tolerability A Study of Advanced INCAGN02390 in Select Malignancies
Hic determinare studium salutis tolerability et parata in efficacia INCAGN02390 participes malignancies gradum provectus.
Location: Hackensack University Medical Center, Hackensack, New Jersey
A Hepatitis (6MHP) cum aut sine CDX MCXXVII-pro-IV Curatio Tempus IIB Carcinoma
Hoc tempus I / II iudicii quam bene et studiis latus effectus vaccini (6MHP) cum aut sine CDX, MCXXVII de scaena curatio opus ad IV IIB melanoma. Vaccina: ut 6MHP, potest auxilium corpus ad effective formae nauigiis interficere immune responsio ut tumore cellulis. Virus immunotherapy elementorum et qualis CDX MCXXVII, potest auxilium corpus invadere feugiat arcu et tumore cellulis crescere possit intercedi pervagata. Hoc est iudicium fieri videatur, ut id quod facit solus et cumulative cum 6MHP CDX MCXXVII habent super mutationes, in immune ratio.
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Et cum Ipilimumab Nivolumab Immunoembolization in his quae sunt aegroti uveam Metastasico Carcinoma in Hepate
Hoc Phase II iudicium et studia ipilimumab nivolumab immunoembolization ubi cum aegris cum uvea melanoma quae propagationem ad iecur. Virus immunotherapy elementorum et qualis ipilimumab nivolumab ac, feugiat oppugnare auxilium corporis cancer cellulis tumor incrementum fortasse facultate et multiplicabatur. Immunoembolization ut tumore cellulis occidere sanguinis damnum debitum ad copia, et develop an immune responsio adversus tumore cellulis. Potest melius operari cum immunoembolization nivolumab dare ipilimumab et in his aegris cum uvea melanoma.
Location: Thomas Universitatis hospitalis, Philadelphia, Pennsylvania
Cyclophosphamide, Fludarabine, tumor infiltrating lymphocytes, in tradendis Aldesleukin et participes sunt Metastasico uveal melanoma
II tempus iudicii quam haec studia atque cyclophosphamide, Fludarabine, tumor infiltrating lymphocytes, et aldesleukin opere ubi agitur de uveal melanoma quae participantium propagationem aliis locis in corpore. Medicamenta in chemotherapy, ut cyclophosphamide et Fludarabine, opere vario quidem modo, ut tumore cellulis luxuries vetuit nasci, aut nectare cellas, per occidere per dederitis eis requiem ab dividere: aut si dederitis eis requiem ab longius procederet. Tumor lymphocytes infiltrating ut an efficens treatment pro uveal melanoma. Aldesleukin stimulate ut album sanguinem cellulis occidere uveal melanoma est amet. Dans cyclophosphamide, Fludarabine, tumor infiltrating lymphocytes, et aldesleukin ultra ut tumore cellulis occidere.
Location: University Cancri Instituti Pittsburgh (UPCI), Pittsburgh, Pennsylvania
CD8 + T lymphocytes cum autologous SLC45A2 specialis cyclophosphamide, Aldesleukin et tractant participes sunt in Ipilimumab Metastasico uveal melanoma
Hoc tempus lb iudicii studiis latus effectus et maxime pondere autologous CD8 positivum (+) SLC45A2 Utilia T lymphocytes, cum datum est una cum cyclophosphamide, aldesleukin et ipilimumab et vide quam bene sunt operari in his quae participantium cum uvea melanoma quae propagationem alibi in corpore. Ut specialized CD8 + T cellulis et T cellulis Inquisitores separate quodque ex ea sic tractare, et sanguinis participem se possunt melanoma scopum cellulis. Sanguineus globulus sunt, tunc particeps ad dedit. Hoc est ut "T cellula nascuntur, illud transferre" vel "Lorem cellula T nascuntur." Medicamenta in chemotherapy, ut cyclophosphamide, ut diversas vias opus in luxuries vetuit nasci ex tumore cellulis, vel occidendo, in ergastula ab eis dividit, intercipiendo quoties libuerit, aut si dederitis eis requiem ab longius procederet. Biological therapies, ut aldesleukin, ex usu quae fiunt organizati qui habitabat in diversis itineribus feugiat nulla movet, ut tumore cellulis et subsisto a growing. Virus immunotherapy elementorum et qualis ipilimumab potest auxilium corpus invadere feugiat arcu et tumore cellulis crescere possit intercedi pervagata. Utilia SLC45A2 dare autologous CD8 + T lymphocytes una cum cyclophosphamide, aldesleukin et ipilimumab potest melius operari in his quae participantium metastatic cum uvea melanoma.
Location: MD Anderson Cancer Center, Texas
Intravenous et Intrathecal Nivolumab dum de morbo affectis patientibus definiens Leptomeningeal
Et hoc tempus / lb iudicii latus effectus et studia optima et rubore laudabunt Intrathecal nivolumab, et quam non operatur bene ubi tandem coniunctim afficient vniuersa sunt intravenous nivolumab leptomeningeal aegris cum morbo. Virus immunotherapy elementorum et qualis nivolumab potest auxilium corpus invadere feugiat arcu et tumore cellulis crescere possit intercedi pervagata.
Location: MD Anderson Cancer Center, Texas
Nivolumab Ipilimumab cum aut sine surgery seu Relatlimab in conspectu aegroti I. Tempus est factor quod potest demi-IV Carcinoma Surgery
Haec studia randomized iudicium II tempus quomodo non etiam cum aut nivolumab ipilimumab relatlimab ante surgery non operatur gradu in his aegris in Australia melanoma-V potest esse remota a surgery. Virus immunotherapy elementorum et qualis nivolumab, ipilimumab et relatlimab potest auxilium corpus invadere feugiat arcu et tumore cellulis crescere possit intercedi pervagata. Agens respectu solis nivolumab ipilimumab vel arte fiat ante relatlimab absumunt temptent normalis textus occurrit minores ponuntur.
Location: MD Anderson Cancer Center, Texas
Et tractant Hepatitis 6MHP Ipilimumab in aegroti sunt spectacula theatrica II, III Carcinoma
Hoc tempus I / II iudicii studiis latus effectus est melanoma VI adiutorium Vaccinum precursor (6MHP) Et vide quam bene sunt et ipilimumab operari in his aegris in scaena II-II melanoma. De vaccina in peptides, ut 6MHP vaccine potest auxilium corpus ad effective formae nauigiis interficere immune responsio ut tumore cellulis. Virus immunotherapy elementorum et qualis ipilimumab potest auxilium corpus invadere feugiat arcu et tumore cellulis crescere possit intercedi pervagata. An nondum notum est magis dare 6MHP Vaccinum et ipilimumab operatur in his aegris cum melanoma.
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Dabrafenib Mesylate, Trametinib et adiutor Vertebrata VI Carcinoma in tractant Hepatitis cum aegroti factor Scaena IV Carcinoma
Hoc tempus I / II iudicii quam bene et studiis latus effectus dabrafenib mesylate, trametinib et melanoma VI adiutorium cum ageretur aegros precursor Vaccinum opus in quarto gradu, Australia melanoma. Trametinib ut tumore cellulis et mesylate Dabrafenib luxuries vetuit nasci quidam enzymes opus ad cellulam incrementum impediret. Vaccina: melanoma, ut auxiliaretur VI precursor vaccine facta Ex melanoma peptides ex proteins, potest auxilium corpus ad effective formae nauigiis interficere immune responsum est quod tumore cellulis exprimere melanoma Utilia antigens. Dabrafenib dare, trametinib et melanoma VI adiutorium precursor vaccine possunt opus melior cum de aegris cum melanoma.
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Acidum valproicum Sunitinib Triticum vel in malo veniendi Metastasis in High Periculum aegroti et uveal melanoma
II pars studiorum randomized iudicio hoc quam summum periculum ne opera sunitinib Triticum vel uvea acidum valproicum (oculorum) Queratose longius partibus corporis. Sunitinib Malate potest prohibere transmissio in annuit incrementum tumore cellulis, ne hae cellulae quo a growing. Acidum valproicum potest immutare et supprimere tumor incrementum expressio quidam genes in uveal melanoma.
Location: Thomas Universitatis hospitalis, Philadelphia, Pennsylvania
Et lymphocytes infiltrating tumor non altus-dose aut Aldesleukin cum autologous dendritic cells in somes cum aegroti Metastasico Carcinoma
This randomized phase II trial studies how well therapeutic tumor infiltrating lymphocytes and high-dose aldesleukin with or without autologous dendritic cells work in treating patients with melanoma that has spread to other areas of the body. Vaccines made from a person's tumor cells and special blood cells (dendritic cells) may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill tumor cells. It is not yet known whether therapeutic tumor infiltrating lymphocytes and high-dose aldesleukin are more effective when given together with or without dendritic cells in shrinking or slowing the growth of melanoma. The clinical benefits of receiving tumor infiltrating lymphocytes (TIL) in combination with the B-Raf proto-oncogene, serine / threonine kinase (BRAF) inhibitor will be studied, in patients who have progressive disease (PD) with using the BRAF inhibitor prior to TIL treatment. Leptomeningeal disease (LMD) is unfortunately a common development in patients with melanoma, with an extremely poor prognosis, translating into an overall survival of only weeks. With the novel approach of combining intrathecal TILs and intrathecal interleukin (IL)-2, researchers hope to induce long term disease stabilization or remission of LMD.
Location: M D Anderson Cancer Center, Houston, Texas
Vorinostat for the Treatment of Class 2 High Risk Uveal Melanoma
This early phase I trial studies how well vorinostat works in treating patients with high risk uveal (eye) melanoma. Researchers are finding that the cells in uveal melanomas are mostly divided into two types: class 1 and class 2. The class 2 cells tend to have a higher chance of moving to other organs in the body, while the class 1 cells mostly stay in the eye. Vorinostat may be able to change class 2 cells into the less aggressive class 1-type cells by "turning on" the genes in the cell that suppresses tumors.
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Ulixertinib in Treating Patients with Stage IV Uveal Melanoma
Hoc Phase II iudicium studiis latus effectus non operatur bene ubi agitur de ulixertinib et quomodo uvea quarto gradu cum aegris melanoma. Ut tumore cellulis Ulixertinib luxuries vetuit nasci tutabantur quidam enzymes opus ad cellulam incrementum.
Location: See Clinical Trials.gov
Carcinoma in Vorinostat tractant aegroti sunt oculi Metastasico
Hoc Phase II iudicium vorinostat opera studiis quam honestus, ubi agitur de aegris cum melanoma alias partes corporis est oculus quae propagationem. Ut tumore cellulis Vorinostat luxuries vetuit nasci tutabantur quidam enzymes opus ad cellulam incrementum.
Location: See Clinical Trials.gov
